The phase 4 study is known as IXORA-R. This study was a head to head study between Taltz and Tremfya. There were a total of 1,027 patients with moderate to severe plaque psoriasis. The primary ...

Eli Lilly courts physicians with blockbuster-topping Taltz data In the June data presentation, 36% of patients treated with Taltz hit both markers at 24 weeks, topping Humira, which saw only 28% ...

The minute-long commercial, featuring lots of bare shoulders, midriffs and swimsuits, promotes a new drug by Eli Lilly and Co. called Taltz that treats red, scaly patches of skin caused by ...

INDIANAPOLIS, Aug. 13, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today Taltz ® (ixekizumab) met the primary and all major secondary endpoints up to week 12 in the Phase 4 ...

Eli Lilly's Taltz and Novartis' Cosentyx have been jockeying for IL-17 inhibitor supremacy with back-and-forth FDA approvals for years. But in the race for a fourth indication, Taltz has come out ...

INDIANAPOLIS, May 22, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved a label update for Taltz ® (ixekizumab ...

Eli Lilly announced that the Food and Drug Administration (FDA) has approved Taltz (ixekizumab) injection for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for ...

Two decades ago, Eli Lilly and Co. boasted just one ... While many new products are fueling Lilly’s turnaround, Taltz, launched in 2016, is an especially key driver. The company spent hundreds ...

Drugmaker Eli Lilly & Co (LLY) said that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (BLA) for its Taltz injection used for the treatment ...